glucagon like peptide 1 glp 1 agonists Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Anesthetic Considerations for Patients Taking

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes

The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.

Arizona OPEN ACCESS PUBLISHED:30 October 2024 CITATION:Chakkera, S

Introduction Our study has two objectives: (1) to evaluate the incidence and severity of food retention observed during esophagogastroduodenoscopies (EGDs) in patients with and without history of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and (2) to create a grading scale to standardize the language regarding food retention

Berberine is not a GLP-1 agonist, though both compounds influence metabolic pathways